Introduction

CD115 (macrophage colony-stimulating factor receptor, or CSF-1 receptor) is the sole cell-surface receptor identified for CSF-1, the predominant growth factor regulating the survival, growth and differentiation of myeloid lineage cells comprising monocytes, macrophages, DCs and osteoclasts. It is encoded by the c-fms proto-oncogene and belongs to the class III receptor tyrosine kinase family. CD115 overexpression has been reported in a wide variety of human tumors (notably breast, ovary, endometrium, cervix, prostate and kidney cancers), where it has been correlated with more aggressive disease. Circulating CSF-1 is found at elevated concentrations in the plasma of patients with epithelial cancers and constitutes a poor prognosis marker, especially in breast, cervical or ovary cancers.

Signaling through the CD115 pathway mediates monocyte survival and differentiation. Interleukin (IL)-6 can upregulate autocrine CSF-1 consumption by monocytes, stimulating their survival and differentiation into macrophages rather than DCs. Skewing of monocyte differentiation toward CD14+CD1a+ dendritic cells (DCs). In line with this observation, H27K15 also drastically inhibits monocyte chemotactic protein-1 secretion and reduces interleukin-6 production; these two molecules are known to be involved in M2-macrophage recruitment. Thus, the non-depleting mAb H27K15 is a promising anti-tumor candidate, able to inhibit osteoclast differentiation, likely decreasing metastasis-induced osteolysis, and able to prevent M2 polarization of TAMs while inducing DCs, hence contributing to the creation of more efficient anti-tumor immune responses.
has been proposed to contribute to tumor-induced immunosuppression. Results from murine models have shown that the CD115/CSF-1 pathway plays a central role in tumor progression through its effects on the differentiation of tumor-associated macrophages (TAMs). TAM infiltration into tumors has been linked with poor prognosis in many cancers. In breast cancer models, CSF-1 was shown to be an important chemoattractant for macrophages and to enhance their infiltration into the primary tumor, contributing to progression. Once at the tumor site, TAMs mediate the angiogenic switch, and they facilitate tumor cell extravasation and metastasis. It is now recognized that TAMs can represent the most abundant immunosuppressive cell population in the tumor microenvironment, recruited by CSF-1 and MCP-1 (CCL2). CSF-1 is known to polarize macrophages toward M2-type. M2-type macrophages that express the hemoglobin scavenger receptor (CD163) are characterized by high FcR-mediated phagocytic capacity associated with regulatory functions. Duluc et al. suggested that human monocytes are skewed to a M2d subtype through autocrine CSF-1 consumption, facilitated by tumor-induced IL-6 production.

CSF-1 is also a main cytokine regulating osteoclast differentiation, as evidenced by the osteopetrotic phenotypes of CD115 or CD115-deficient mice. Tumor cells metastatic to bone and producing CSF-1 stimulate the differentiation of osteoclasts that induce bone degradation and pain in cancer patients. Not only the differentiation but also the bone-resorption activity of human osteoclasts is dependent on CSF-1/CD115 in addition to receptor activator of NF-kappaB (RANK)/RANKL. Both cell-surface and secreted CSF-1 expressed by bone-metastatic tumor cells can contribute to osteoclast formation.

The CD115 pathway is therefore implicated at multiple levels during cancer progression and its inhibition represents a promising therapeutic strategy. MAbs to CD115 have been previously described to block the receptor signaling (ref. 36 and patent WO2009/026303); however, one difficulty in the clinical use of anti-CD115 MAbs is the ubiquitous expression and function of CD115 in normal myeloid cells, evidenced by the severe phenotype of CD115-knockout mice. Moreover, the use of MAbs that block the formation of the CSF-1/CD115 complex affects the physiological degradation pathway of CSF-1 and results in massively elevated plasma CSF-1 levels, which may lead to rebound effects in treated patients.

The development of new anti-CD115 MAbs is needed to overcome these important drawbacks. We have therefore selected a new MAb to CD115 (patent WO2009/112245), H27K15, that exhibits inhibitory effects on the receptor function. In contrast to other anti-CD115 MAbs (ref. 36 and patent WO2009/026303), H27K15 does not compete with ligand binding and exhibits different effects on signal transduction and cellular trafficking. This MAb shows interesting properties that may make it suitable for clinical use as a cancer therapy. First, H27K15 downregulates osteoclast differentiation and activity, which could block metastasis-induced bone degradation. Second, it inhibits monocyte differentiation into CD163+CD64+ M2-polarized suppressor macrophages, rather driving their differentiation toward CD14+CD1a+ DCs. Third, this antibody differs from other anti-CD115 MAbs by affecting only marginally the survival of monocytes. Thus, mAb H27K15 is a promising candidate for cancer immunotherapy that could help avoid rebound effects and toxicity in treated patients.

**Results**

**Anti-CD115 MAbs differently affect CSF-1 binding.** We generated a new MAb directed against human CD115, referred to as CXIG6, which stained a CD115-transfected NIH/3T3 cell line, but not untransfected cells (Supplemental Methods and Fig. S1). The MAb is an IgG1κ recognizing an epitope located in the N-terminal domain of human CD115 (data not shown) and does not cross-react with murine CD115. It was found to dose-dependently decrease MMP-9 production by monocyte-derived osteoclasts differentiated with CSF-1 and RANKL (Fig. S2). It also decreased the CSF-1-dependent phosphorylation of CD115 intracellular tyrosine (Tyr) 708 in NIH/3T3-CD115 cells (data not shown). To evaluate the potential effects of this MAb as a tool for cancer immunotherapy, we derived a humanized IgG1 version, H27K15, as described in the Supplemental Methods. Like the parental mAb, H27K15 decreased the CSF-1-dependent phosphorylation of CD115 Tyr708 in NIH/3T3-CD115 cells (data not shown). ELISA showed that H27K15 did not cross-react with other TK receptors sharing sequence homologies with CD115 (data not shown), suggesting that the MAb would selectively target CD115 in humans.

MAbs 2–4A5 and 1.2SM (WO2009/026303) are other anti-CD115 MAbs previously shown to inhibit the CSF-1/CD115 pathway. We aimed to analyze and compare the modes of action and biological effects of these two anti-CD115 MAbs with those of H27K15. mAb 1.2SM was produced on a similar human IgG, backbone as H27K15, while mAb 2–4A5 was available only as a rat IgG. Their competition with CSF-1 binding was studied by ELISA on immobilized recombinant CD115 extracellular domain (ECD)-Fc. As shown on Figure 1A, mAb H27K15 had a minimal effect on CSF-1 binding to CD115, with only around 10% inhibition at highest concentrations, reflecting the fact that its epitope is located outside of the CSF-1-binding site (data not shown). In contrast, mAbs 1.2SM and 2–4A5 totally prevented CSF-1 binding to CD115, with a slightly lower EC50 for mAb 1.2SM than for 2–4A5 in this assay (0.17 and 0.40 μg/ml, respectively).

Using Quartz Crystal Microbalance (QCM), mAbs 1.2SM and 2–4A5 showed high affinities for recombinant CD115 ECD, with K_d of 1.3 and 1.9 nM respectively (Fig. 1B). H27K15 differed from 1.2SM and 2–4A5 by its faster dissociation rate. Its K_d in this setting was of 16.9 nM, one-log higher than for mAbs 1.2SM or 2–4A5.

These results show that mAbs 1.2SM and 2–4A5 are high affinity anti-CD115 MAbs that block CSF-1 binding to its receptor, whereas H27K15 has intermediate affinity to CD115 and does not prevent CSF-1/CD115 binding.

**Diverging effects of anti-CD115 MAbs on receptor signaling and trafficking.** The anti-CD115 MAbs were then tested in a phosphorylation assay using the myeloid leukemia
cell line OCI-AML5, expressing detectable surface levels of CD115 (Fig. S3). In the absence of CSF-1, the mAbs had no effect on CD115 phosphorylation, showing that they had no agonistic activity (data not shown). Stimulation by CSF-1 induced CD115 phosphorylation on Tyr723 and activation of the PI3 kinase pathway, as indicated by Akt phosphorylation (Fig. 2A). Compared with the control IgG, rituximab, H27K15 decreased the CSF-1-dependent phosphorylation of CD115 Tyr723 and Akt Ser473 (Fig. 2A). This effect was partially dependent on the presence of H27K15 Fc region, since F(ab’)2 derived from 1.2SM had the same effect (not shown), indicating that this inhibitory effect was independent from the mAb Fc. The small-molecule CD115 tyrosine kinase inhibitor GW258041 also potently inhibited CD115 and Akt phosphorylation.

After CSF-1 binding, the cytokine-receptor complex is normally internalized and degraded. The band corresponding to total CD115 was more intense in the presence of mAbs 1.2SM and 2–4A5 compared with their respective isotype controls, suggesting that these anti-CD115 mAbs inhibited the receptor degradation. CD115 degradation was also inhibited in the presence of GW2580 (Fig. 2A). In contrast, in the presence of mAb H27K15, total CD115 was not increased, suggesting that degradation of the receptor-ligand complex could still occur.

We further investigated whether the CSF-1-dependent internalization of CD115 was modified in the presence anti-CD115 mAbs. This was analyzed using transfected EL4-CD115 cells, devoid of detectable surface FcγR (data not shown). These cells were brightly stained by mAbs H27K15 or 1.2SM (Fig. 2B, upper left panel). In contrast, mAb 2–4A5 was inefficient in staining CD115 on these cells (Fig. 2B, lower left panel), possibly due to a poor accessibility of its membrane-proximal epitope. For this reason, only mAbs H27K15 or 1.2SM were tested. EL4-CD115 cells were stimulated with CSF-1 in the presence of anti-CD115 mAbs before incubation at 37°C for 30 min, after which remaining cell-surface CD115 was measured by flow cytometry (FC) using another mAb (clone 12–3A3–1B10, Fig. 2B, lower left panel). This mAb did not compete, or only minimally, with the binding of either CSF-1 or the other anti-CD115 mAbs tested (data not shown). As shown in Figure 2B (right panel), when EL4-CD115 cells were stimulated with CSF-1, the level of surface CD115 rapidly diminished, reflecting the receptor internalization. This occurred in the presence or absence of irrelevant IgG, rituximab. mAb H27K15 did not modify the CSF-1-induced disappearance of CD115 from the cell surface, suggesting that the receptor had been internalized after binding both CSF-1 and the
or with 1.2SM F(ab’)_2 at concentrations above 0.1 μg/ml (Fig. 3A). With H27K15, osteoclast numbers were reduced less dramatically. Its inhibitory effect was Fc-dependent, since H27K15-derived F(ab’)_2 showed much weaker activity in this assay. Fab fragments alone did not have any significant inhibitory effect (data not shown).

Since mAb H27K15 could down-regulate osteoclast differentiation, its effects were tested in another model measuring both osteoclast differentiation and their bone resorption activity, using human CD34⁺ cells as precursors. These were cultured for 10 d on bone slices in the presence of CSF-1 and RANKL, and of mAb H27K15 or irrelevant IgG1 rituximab, added at 1 μg/ml from the first day of culture. In line with the previous results, significant reduction of secreted TRAP5b was observed with mAb H27K15 (Fig. 3B). In addition, bone resorption measured by titration of C-terminal cross-linked telopeptides of type I collagen (CTX) was inhibited. Microscopic images of TRAP staining at day 10 (Fig. 3C) illustrate the reduced osteoclast numbers in cultures treated with H27K15.

In summary, the ligand-blocking mAbs had a dramatic effect on osteoclast differentiation, which was totally inhibited after culture at concentrations above 0.1 μg/ml. In contrast, mAb H27K15 did not eradicate osteoclasts but diminished their number and osteolytic activity.

Complete blockade of CD115 signaling affects cell survival in macrophage differentiation cultures. We then studied the effects of the anti-CD115 mAbs or F(ab’)_2 in a model of macrophage differentiation from blood monocytes. CD14⁺ monocytes from different blood donors were allowed to differentiate in the presence of both GM-CSF and CSF-1, known to induce macrophage differentiation toward M1- and M2-polarized populations, respectively. The CD115 tyrosine kinase inhibitor GW2580, known to inhibit the CSF-1-dependent proliferation of human monocytes and the differentiation of murine macrophages in vitro, was tested in the same assay.

Observation of day-6 cultures showed that cells with mononuclear phagocyte-like morphologies were able to differentiate in cultures treated with H27K15. In contrast, the CD115-blocking mAbs 2–4A5 and F(ab’)_2 derived from 1.2SM induced almost total cell death. Results from one representative donor are shown.
on Figure 4A. Cell counts at day 6 were comparable between H27K15- and control IgG1-treated cultures, but drastically reduced in the presence of 2–4A5 and 1.2SM F(ab')2. F(ab')2 from mAb 1.2SM showed similar high cytotoxicity at all concentrations tested (equimolar to 0.1–10 μg/ml full IgG) while mAb 2–4A5 induced total cell death at 1 and 10 μg/ml. With GW2580, cytotoxicity was less drastic at the dose tested (1 μM), but only 70% of the cells remained alive at day 6 compared with untreated cultures. Thus, the anti-CD115 mAbs differently affected cell viability in this monocyte-to-macrophage differentiation model: the CSF-1-blocking mAbs prevented cell survival, while mAb H27K15 was not cytotoxic to differentiating cells.

mAb H27K15 inhibits macrophage polarization toward the M2 type. Because H27K15, but not the other anti-CD115 mAbs, maintained cell viability in the monocyte-to-macrophage differentiation model, we studied its effects on the cell phenotypes and on cytokine production. Day-6 cultures were analyzed by FC for cell-surface expression of the human IgG Fc receptors CD64 (FcγRI), CD32 (FcγRII) and CD16 (FcγRIII). Among those receptors, CD16 and CD64 are expressed at high levels by M2-polarized macrophages induced by CSF-1.11,27 Surface expression of CD64 was drastically reduced after treatment with H27K15 or with the CD115 TK inhibitor GW2580, compared with rituximab or untreated cultures, as shown in (Fig. 4B and C). CD64 downregulation by H27K15 occurred in cultures from all blood donors tested (p = 0.029, n = 4). CD64 expression was found to be concomitantly reduced (Fig. 4D and data not shown). Downregulation of CD16 and CD64 were also observed with GW2580, although not in all donors tested (data not shown), suggesting that FcγR downregulation was not caused by the binding of the mAb Fc region to CD16 or CD64 followed by internalization of the complex, but rather a consequence of CD115 function blockade. While H27K15 potently inhibited expression of CD64 and CD16, CD32 was hardly affected (Fig. 4B and data not shown), suggesting that the mAb had led to the emergence of a cell population likely related to DCs, which are CD32+ but barely express CD16 and CD64.45 F(ab')2 derived from H27K15 showed only a weak, non-statistically significant effect on CD64 expression (Fig. 4C), as on CD16 expression (data not shown), showing that this effect of H27K15 was Fc-dependent.

We then analyzed the expression of CD163 and CD206, two phenotypic markers of M2-polarized macrophages.26,28,31 After differentiation in GM-CSF and CSF-1, the vast majority of cells were CD206-positive and a smaller proportion of cells also expressed CD163 (Fig. 4D). Cells exhibiting both surface markers represented from 7.1 to 16.4% of the total population without treatment (data not shown). In control cultures, CD163+ cells were CD16-bright and CD64-positive (Fig. 4D), a phenotype previously described for CSF-1-induced M2 macrophages.21,25,27 Culture with mAb H27K15 inhibited the differentiation of osteoclasts differentiated on bone slices was performed after 10 d of culture with CSF-1 and RANKL.

Figure 4B and C). Representative microscopic images of the effect of mAb H27K15 on cultures from the same donor as in (B), compared with control IgG1. TRAP staining of osteoclasts differentiated on bone slices was performed after 10 d of culture with CSF-1 and RANKL in presence of the mAbs. Original microscope magnification × 100.
**Figure 4.** H27K15 is not cytotoxic to monocytes cultured in GM-CSF and CSF-1 but inhibits M2-type macrophage differentiation. CD14⁺ monocytes were cultured with GM-CSF alone (from day 0 to day 3) and GM-CSF plus CSF-1 (from day 3 to day 6), in the presence of anti-CD115 or control mAbs at the indicated concentrations, F(ab’), at corresponding equimolar concentrations (0.06, 0.6 or 6 μg/ml) or the CD115 tyrosine kinase inhibitor GW2580 at 1 μM. (A) Macrophage viability after 6 d. Shown are the mean cell counts in 3 wells ± SD obtained in each culture condition from one representative blood donor. (B) Inhibition of CD64 expression after monocyte differentiation in the presence of mAb H27K15 (10 μg/ml) or GW2580, compared with their respective negative controls rituximab or no treatment. Dot plots represent CD64 and CD32 staining of live cells derived from one blood donor representative of 4 tested. (C) Medians of CD64 fluorescence intensities in monocyte differentiated from the same donor in the presence or absence of GW2580, H27K15 or rituximab (both at 0.1, 1 or 10 μg/ml), or their derived F(ab’), at equimolar concentrations. *Mann-Whitney’s two-tailed test p = 0.029 (n = 4 donors) between CD64 MFI with mAb H27K15/CD64 MFI in untreated culture compared with rituximab. (D) Middle panels: Dot plots represent CD163 and CD206 surface expression in monocytes differentiated with GM-CSF and CSF-1 in the presence of either H27K15 or control rituximab (1 μg/ml). Resulting percentages of CD163⁺CD206⁺ cells are indicated. Histogram overlays of CD16, CD32 and CD64 fluorescence in the live cell population (plain lines) and in the CD163⁺CD206⁺ (bold lines) subpopulation are shown for H27K15- (right) or rituximab-treated (left) cultures. Dotted lines: isotype controls. Data obtained from one blood donor representative of 4 tested. (E) Percentages of CD163⁺CD206⁺ macrophages in cultures from the same donor after differentiation in the presence of H27K15 or rituximab (1 μg/ml), or the corresponding F(ab’), (0.6 μg/ml), or no reagent. *Mann-Whitney’s two-tailed test p = 0.029 (n = 4 donors) between % CD163⁺ cells with mAb H27K15/% CD163⁺ cells in untreated culture compared with rituximab. (F) MCP-1/CCL2 and IL-6 were titrated in culture supernatants from monocyte-derived cells from 4 different blood donors after a 6-d culture with GM-CSF and CSF-1 in the presence of mAb H27K15 or isotype control rituximab (both at 1 μg/ml). Shown are the median percentages of variation in MCP-1/CCL2 (left) or IL-6 (right panel) produced in rituximab- or H27K15-treated cultures vs. untreated cultures. *Mann-Whitney’s two-tailed test p < 0.05 between MCP-1 production with mAb H27K15/MCP-1 production in untreated culture compared with rituximab.
IL-6 alone can switch monocyte differentiation from DCs, which may contribute to cancer-induced immunosuppression. IL-6 produced by carcinoma cells inhibit the differentiation of monocytes toward DCs.

It has been reported that both CSF-1 and IL-6 inhibit the differentiation of M2-polarized macrophages. Strikingly, anti-CD115 mAb H27K15 downregulates IL-6 production by differentiating monocytes. As such, H27K15 is a potent inhibitor of MCP-1 secretion and significantly inhibited the effect of H27K15 on MCP-1 production, suggesting that each combination of the 3 F(ab’)2 had a significant effect on MCP-1 levels compared with untreated control cultures (data not shown). We investigated the contributions of FcγR in H27K15 mode of action, by adding blocking F(ab’)2 to CD16, CD32 and CD64 alone or in combinations to the monocyte cultures (Fig. S5). Only the combination of the 3 F(ab’)2 significantly inhibited the effect of H27K15 on MCP-1 production, suggesting that each FcγR may contribute by binding the mAb Fc region.

IL-6 levels between 19 and 134 pg/ml were found in the supernatants from control rituximab-treated cultures. They were also decreased in all donors upon culture with H27K15 (from 1.8- to 4-fold, Fig. 4F), although to a lesser extent than MCP-1 levels. Thus, mAb H27K15 is a potent inhibitor of MCP-1 secretion and downregulates IL-6 production by differentiating monocytes. As evidenced by these changes in cytokine/chemokine production and in cell phenotypes, targeting CD115 with mAb H27K15 inhibits the differentiation of M2-polarized macrophages.

mAb H27K15 skews monocyte differentiation from macrophages toward DCs. It has been reported that both CSF-1 and IL-6 produced by carcinoma cells inhibit the differentiation of DCs, which may contribute to cancer-induced immunosuppression. IL-6 alone can switch monocyte differentiation from DC to macrophages, by upregulating CD115 expression and facilitating CSF-1 consumption. We therefore analyzed the expression of CD1a and CD14, as DC and monocyte/macrophage markers, respectively, in addition to CD163 and CD206 in cultures from monocytes stimulated for 6 d with GM-CSF and CSF-1 (Fig. 5A). In control cultures, depending on the blood donors, the majority of cells were either CD14+CD1a− macrophages, or CD14+CD1a+ cells of immature or intermediate differentiation stage. A population of CD1a+CD14+CD163− DCs was also present, representing 3% to 28% of the live cell population in monocyte from 7 different blood donors differentiated with GM-CSF and CSF-1 in presence of 1 μg/ml H27K15, compared with control rituximab. **p = 0.015 and *p = 0.03 using Wilcoxon’s signed rank test. CD83 expression was analyzed by FC in monocytes cultured for 6 d with GM-CSF and CSF-1 in presence or absence of mAb H27K15 or control IgG1 rituximab. CD1a+CD14+ cells (green) are shown in the corresponding quadrants and percentages of CD1a+CD14+ and CD14+CD1a− cells are indicated in the corresponding quadrants and percentages of CD163+CD206+ cells are shown in red. (B) Increase in DCs (CD1a+CD14+ upper panel) and decrease in macrophages (CD14+CD1a− lower panel) within the live cell population in monocyte from 7 different blood donors differentiated with GM-CSF and CSF-1 in presence of 1 μg/ml H27K15 compared with control rituximab. **p = 0.015 and *p = 0.03 using Wilcoxon’s signed rank test. (C) CD83 expression was analyzed by FC in monocytes cultured for 6 d with GM-CSF and CSF-1 in presence of mAb H27K15, without (upper panels) or after LPS stimulation (lower panels) for an additional 24 h. Histograms showing CD83 staining (black lines) compared with isotype control (gray lines) in the CD1a+CD14+ and CD1a−CD14− populations. Results from one blood donor representative of 2 tested in independent experiments.

This CD163+CD16+CD64+ macrophage population, as shown in (Fig. 4D and E) for one representative donor. The percentages of CD206+CD163− cells decreased from 2.5- to 4-folds in cultures treated with 1 μg/ml H27K15 compared with rituximab (Fig. 4E and data not shown, p = 0.029, n = 4). F(ab’)2 derived from H27K15 had weak or no effect on CD163 expression, again indicating that the Fc region of the anti-CD115 mAb was involved in its mode of action.

The chemokine MCP-1/CCL2 and IL-6 are two soluble factors implicated in M2 macrophage polarization. Strikingly, in all donors tested, production of MCP-1 was drastically suppressed when monocytes differentiated with GM-CSF and CSF-1 in the presence of mAb H27K15 (Fig. 4F).

MCP-1 levels ranged from 317 to 17,021 pg/ml in the supernatants from control rituximab-treated cultures. They were reduced to levels of 81 to 172 pg/ml after differentiation in the presence of H27K15, representing a decrease from 4-folds to 2-log. MCP-1 inhibition by H27K15 was Fc-dependent, since F(ab’)2, were less potent in similar conditions (Fig. S4) and Fab fragments did not decrease MCP-1 levels compared with untreated control cultures (data not shown). We investigated the contributions of FcγR in H27K15 mode of action, by adding blocking F(ab’)2 to CD16, CD32 and CD64 alone or in combinations to the monocyte cultures (Fig. S5). Only the combination of the 3 F(ab’)2 significantly inhibited the effect of H27K15 on MCP-1 production, suggesting that each FcγR may contribute by binding the mAb Fc region.

IL-6 levels between 19 and 134 pg/ml were found in the supernatants from control rituximab-treated cultures. They were also decreased in all donors upon culture with H27K15 (from 1.8- to 4.4-fold, Fig. 4F), although to a lesser extent than MCP-1 levels. Thus, mAb H27K15 is a potent inhibitor of MCP-1 secretion and downregulates IL-6 production by differentiating monocytes. As evidenced by these changes in cytokine/chemokine production and in cell phenotypes, targeting CD115 with mAb H27K15 inhibits the differentiation of M2-polarized macrophages.
In contrast, culture with mAb 1.2SM even at low concentrations resulted in monocyte death within 24 h (52 ± 6% at 0.01 μg/ml and 61 ± 5% at 1 μg/ml, n = 5, data not shown). This cytotoxic effect was also observed with 1.2SM-derived F(ab’)_2 and thus independent from its Fc fragment. mAb 2–4A5 appeared less cytotoxic than 1.2SM at low concentrations (Fig. 6A, right panel), but it showed dose-dependent toxicity and up to 73% mortality (n = 2) was observed with 10 μg/ml mAb.

In summary, as shown schematically in Figure 6B, mAbs that block ligand binding to CD115 and totally inhibit CD115 signaling also induce rapid monocyte death. This effect alone might explain the complete lack of monocytic differentiation observed toward either osteoclasts (with CSF-1 and RANKL) or macrophages (with GM-CSF and CSF-1) in the presence of mAbs 2–4A5 or 1.2SM. In contrast, the anti-CD115 mAb H27K15, which does not prevent CSF-1 binding but down-modulates CD115 signaling reduces osteoclast differentiation and activity and skews monocyte differentiation from M2-macrophages toward DCs, without blocking CSF-1 degradation.

Ligand-blocking anti-CD115 mAbs induce rapid monocyte death. Models of osteoclast or macrophage differentiation described above utilized blood monocytes as precursor cells. In all cases, ligand-blocking anti-CD115 mAbs 2–4A5 or 1.2SM drastically prevented cell differentiation. Monocyte survival is known to require signaling through CD115, which can be mediated by autocrine CSF-1. We therefore studied the effects of the different mAbs on the viability of primary blood monocytes, cultured in medium containing FCS, but in the absence of exogenous human CSF-1. Figure 6A (left panel) shows that after 1-d culture, only a minor decrease in monocyte viability was observed in the presence of mAb H27K15 (mean ± SEM: 6% ± 2% at 0.01 μg/ml and 21 ± 5% at 1 μg/ml, n = 5 donors, data not shown).

In contrast, culture with mAb 1.2SM even at low concentrations resulted in monocyte death within 24 h (52 ± 6% at 0.01 μg/ml and 61 ± 5% at 1 μg/ml, n = 5, data not shown). This cytotoxic effect was also observed with 1.2SM-derived F(ab’)_2 and thus independent from its Fc fragment. mAb 2–4A5 appeared less cytotoxic than 1.2SM at low concentrations (Fig. 6A, right panel), but it showed dose-dependent toxicity and up to 73% mortality (n = 2) was observed with 10 μg/ml mAb.

In summary, as shown schematically in Figure 6B, mAbs that block ligand binding to CD115 and totally inhibit CD115 signaling also induce rapid monocyte death. This effect alone might explain the complete lack of monocytic differentiation observed toward either osteoclasts (with CSF-1 and RANKL) or macrophages (with GM-CSF and CSF-1) in the presence of mAbs 2–4A5 or 1.2SM. In contrast, the anti-CD115 mAb H27K15, which does not prevent CSF-1 binding and only reduces CD115 signaling via Akt, is minimally cytotoxic to monocytes, while redirecting CSF-1-dependent myeloid cell differentiation, inhibiting M2-type macrophages and inducing dendritic cells.
We have shown that different mAbs directed against the same target, CD115, could have diverse and even diverging effects at the molecular and cellular levels. These appear directly related to their differential effects on CSF-1 binding to its receptor. Two mAbs that potently blocked CSF-1/CD115 binding, even through distant epitopes on CD115 (D1-D2 for 1.2SM, vs. D4-D5 for 2–4A5; patent WO2009/026303 and data not shown), totally inhibited CD115 phosphorylation and signaling. As expected based on the receptor biology, they also prevented the receptor internalization and blocked CD115 on the cell surface. This had drastic consequences on myeloid lineage cells, as neither macrophages nor osteoclasts could differentiate from cultured monocytes. Monocytes rapidly died in the presence of ligand-blocking mAbs, with mAb 1.2SM showing the strongest effect, possibly reflecting its highest affinity to CD115. Thus, the complete blockade of CD115 signaling in the absence of exogenous human CSF-1 resulted in rapid monocyte death. When monocytes were cultured with CSF-1 and RANKL or with CSF-1 and GM-CSF, signaling through either the RANK or GM-CSF receptor pathways could not compensate for the lack of CD115 stimulation to sustain osteoclast or macrophage differentiation. Osteoclast differentiation is dependent on CD115, upstream of the RANK/RANKL pathway. GM-CSF has been shown to induce CSF-1 production in monocytes. Since the total blockade of CD115 signaling resulted in cell death even in the presence of GM-CSF, our results, which are in line with former studies, suggest that GM-CSF mediates monocyte survival through the sole induction of CD115 ligand.

mAb H27K15 showed a different mode of action because it did not block CSF-1 binding and inhibited only partially CD115-mediated signaling. Importantly, internalization and degradation of the receptor-ligand complex still occurred. Our results suggest that the trimeric H27K15/CD115/CSF-1 complex can be internalized from the cell surface and degraded, concomitant with a decrease in receptor-mediated signal transduction. mAb H27K15 had only a weak effect on monocyte viability, suggesting that low intensity signaling through CD115 is sufficient to support monocyte survival, but not their full differentiation into either M2-type macrophages or bone-resorbing osteoclasts.

The elimination of circulating CSF-1 is physiologically mediated through CD115 binding, internalization and degradation. One major issue in the clinical use of anti-CD115 mAbs is the dramatic several-log increase of plasma CSF-1 that has been observed in preclinical models upon use of ligand-blocking mAbs. Such elevation of circulating CSF-1 may lead to severe rebound effects following withdrawal of the treatment or in organs not accessible to mAbs. Our results show that ligand-blocking mAbs inhibit CSF-1-dependent CD115 degradation and that mAb 1.2SM immobilizes the receptor on the cell surface. mAb H27K15, in contrast, did not block CD115 internalization or degradation, suggesting that in vivo treatment may not result in the accumulation of plasmatic CSF-1. This remains to be verified in a relevant animal model, still lacking because mAb H27K15 recognizes only human and chimpanzee CD115, and in clinical trials. A transgenic mouse strain is currently being generated to provide a model for preclinical proof-of-concept.

When present during monocyte differentiation, in the presence of GM-CSF and CSF-1, mAb H27K15 inhibited the generation of trophic- or M2-type macrophages. This anti-CD115 mAb drastically inhibited the expression of CD163, the scavenger receptor marker of M2-polarized macrophages. CD163 expression is induced during differentiation with CSF-1, while the expression of the mannose receptor CD206 is rather dependent on GM-CSF. In line with these results, CD115 inhibition affected CD163, but not CD206 expression. M2-type macrophages are also characterized by their high phagocytic and IgG binding capacities, related to surface expression of several FcγRs. The expression of CD64/FcγRI and CD16/FcγRIII was drastically downregulated on differentiating cells treated with H27K15, while CD32/FcγRII was hardly affected. This modulation of FcγR expression reflects monocyte differentiation into CD14+CD163+ DCs instead of CD14+CD163- DCs instead of CD14+CD14+CD163- macrophages. Indeed, monocyte-derived DCs are known to express CD32, but barely CD16 and CD64, if any.

The Fc region of mAb H27K15 participates in its mode of action since the F(ab’)2, alone displayed much weaker biological activities in both CSF-1-dependent signal transduction and monocyte differentiation assays. Monomeric Fabs did not show any CD115 inhibitory activity, suggesting that dimerization of CD115 through H27K15 F(ab’)2 might perturbate the receptor function, possibly by preventing conformational changes required for signal transduction. The role of FcγRs can be central for the effect of therapeutic mAbs. An antibody may simultaneously bind to a cell-surface antigen with its variable region and to an activating or inhibitory FcR via its Fc region on the same cell, a phenomenon originally described by R.J. Kurlander and more recently termed "Scorpio effect." Our results indicate that co-engagement of cell-surface CD115 with an FcγR expressed on the same cell or on a neighboring cell is required for the (full) function-blocking effect of mAb H27K15. OCI-AML5 cells are CD16+CD32+CD64+ (Fig. S3), suggesting that the anti-CD115 mAb may cross-link CD32 with CD115 on their surface. In monocytes, which express a range of FcγR including CD32a and CD64, only the combination of blocking F(ab’)2 to CD16, CD32 and CD64 significantly affected H27K15 activity on MCP-1 production, suggesting that several FcγR may be involved through binding the mAb Fc region.

The cross-linking of FcγR with CD115 through mAb H27K15 may not only be involved in the mAb mode of action on the receptor inhibition, but also directly contribute to its effects on myeloid cell differentiation. Indeed, cross-linking FcγR on monocytes has been shown to favor their differentiation toward DCs. Together with the downregulation of the CD115 pathway, FcγR cross-linking may explain the DC-inducing effect of mAb H27K15.

A striking result was the potent suppression of MCP-1/CCL2 production by H27K15 in monocytes stimulated with GM-CSF and CSF-1. MCP-1/CCL2 has a main role in the recruitment of M2-polarized TAM and represents a promising target for cancer.
immunotherapy. The secretion of IL-6 was also reduced upon CD115 inhibition by H27K15 or GW2580 in all donors. MCP-1 and IL-6 are inducible by each other and their combination is known to induce M2-type macrophage polarization. CSF-1 has formerly been shown to stimulate the production of both IL-6 and MCP-1. In turn, IL-6 can stimulate M2 macrophage generation by facilitating autocrine CSF-1 consumption. Thus, one mechanism by which mAb H27K15 may block monocyte/macrophage generation by facilitating autocrine CSF-1 consumption is known to induce M2-type macrophage polarization.

Corresponding values were subtracted for each hCD115 concentrations tested. Data were analyzed using Evaluation Software (Attana) and a simple 1:1 model for data fitting.

**CD115 internalization in EL4-CD115 cells.** EL4-CD115 cells were pre-incubated in ice-cold medium containing 10 μg/ml of each mAb or 100 ng/ml CSF-1 (ImmunoTools). The temperature was raised to 37°C. After 30 min, cells were transferred on ice and surface CD115 was detected by FC using mAb 12–3A3–1B10 (eBioscience). Median fluorescence intensities (MFI) were immediately measured on a FACS CANTO II flow cytometer (BD Bioscience). The percentages of CD115 internalization were calculated as follows: 100–100*(Isotype control MFI)/(untreated control MFI).

**CD115 phosphorylation assay.** OCL-AML5 cells (DSMZ) were treated with 100 ng/ml CSF-1 (ImmunoTools) during 3 min at 37°C in the presence of anti-CD115 or control mAbs (1 μg/ml) added to the culture medium 1 h before stimulation, or of the CD115 kinase inhibitor GW2580 (1 μM, LC Laboratories) or vehicle. Protein extracts were analyzed by western blot using antibodies to CD115 (C-20, Santa Cruz Biotechnology), phospho-Tyr CD115, phospho-Ser Akt (Cell Signaling Technology) and β-actin (Sigma).

**Osteoclast differentiation from human monocytes.** CD14+ monocytes from blood donors having given informed consent (EFS Alsace) were cultured in 96-well plates with serial dilutions of mAbs or F(ab’)2, CSF-1 (ImmunoTools) and RANKL (PeproTech) were added at respectively 25 and 40 ng/ml and cells were allowed to differentiate in the presence of mAbs or F(ab’)2, for 7 to 8 d. Secreted TRAP5b was titrated using the MicroVue™ TRAP5b EIA kit (Quidel).

**Osteoclast differentiation from human CD34+ cells and activity assay.** Human CD34+ cells (Lonza) were cultured on bovine bone slices (IDS Ltd) with 8.25 ng/ml CSF-1 and 16.5 ng/ml RANKL (OCP BulletKit®, Lonza). At day 7, medium was replaced and cells were cultured for 3 additional days, allowing them to resorb bone. mAb H27K15 or rituximab were added at days 0, 2, 4, 7, 8 and 9, OPG (PeproTech) at day 0 and E64 (Sigma-Aldrich) at day 7. Secreted TRAP5b and CTX were titrated by ELISA (BoneTRAP® and CrossLaps® kits, IDS Ltd).

**Human macrophage differentiation assay.** CD14+ monocytes were cultured in complete RPMI-Glutamax™ medium containing GM-CSF alone (10 ng/ml, PeproTech) from day 0 to day 3 and GM-CSF (2 ng/ml) plus CSF-1 (10 ng/ml, ImmunoTools) from day 3 to day 6. Antibodies, F(ab’)2, or the CD115 TK inhibitor GW2580 (LC Labs) were added at day 0 and day 3. At day 6, cells were counted (5 microscope fields/well), harvested and pools of triplicate wells were analyzed by FC using antibodies from BD Bioscience. For staining surface FcyR, anti-CD16 clone 3G8, anti-CD32 clone 3D3 (recognizing both FcγRIIa and FcγRIIIb), and anti-CD64 clone 10.1 were used. The fact that clones 3G8 and 10.1 can compete with Fc fragments for binding CD16 and CD64, respectively, did not prevent immunostaining after macrophage differentiation in the presence of IgG. Secreted cytokines were titrated by multiplex (Bioplex, Bio-Rad).

**Methods**

**Antibodies.** mAb H27K15 (patent application WO2009/112245) is a humanized anti-CD115 mAb derived from murine mAb CXIIIG6 as described in the Supplemental Methods. mAb 1.2SM is a human anti-CD115 mAb described in patent application WO2009/026303. The variable regions of each of these mAbs were fused with a human IgG1 constant region (GeneBank accession numbers J00241 and J00228). MAbs H27K15, 1.2SM and rituximab (http://www.drugbank.ca/drugs/DB00073) were produced in CHO cells and purified as described in the Supplemental Methods. Rituximab was also kindly provided by Roche. The rat anti-human CD115 IgG, 2–4A5 (Neomarker, Santa Cruz or GeneTex) was generated and characterized by C.J. Sheer et al. Absence of endotoxin contamination in the mAb preparations was assessed using a L.A.L. test (Endosafe™ PTS, Charles River). F(ab’)2 were produced by pepsin digestion of H27K15, 1.2SM or rituximab using Pierce® F(ab’)2 preparation kit. Their purity was between 96% and 100% after gel filtration.

**Competition experiments by ELISA.** Serial dilutions of antibodies or human CSF-1 (GeneArt) were incubated with a fixed concentration of biotinylated CSF-1 in 96-well plates (Maxisorp, Nunc) coated with recombinant human CD115 ECD-Fc (R&D Systems). Plate-bound CSF-1 was revealed with streptavidin-HRP (Southern biotech) followed by 3,3’,5,5’-tetramethylbenzidine (TMB) Substrate (Sigma). Optical densities (OD) were recorded on a Tecan plate reader.

**Affinity measurements by QCM.** The affinities of anti-CD115 mAbs for human CD115 ECD were measured using the QCM technology on Attana 200 (Attana). Monoclonal antibodies were immobilized on LNB chips (Attana) and recombinant CD115 ECD (D1-D5, GeneArt) was injected for 70 sec, before a post-injection phase of 180 sec. Buffer was used as a reference and corresponding values subtracted for each hCD115 concentrations tested. Data were analyzed using Evaluation Software (Attana) and a simple 1:1 model for data fitting.
Monocyte viability assay. CD14+ monocytes were cultured for 1 d in RPMI-1640 medium (Sigma) with 10% FCS and serial dilutions of mAbs or F(ab`)2. Cell survival was assessed using the CellTiter-Glo® Luminescence Cell Viability Assay (Promega) and light emission was recorded on a TriStar LB 941 reader (Berthold Technologies).

Additional methods. Detailed methodologies are provided in the Supplemental Methods.

Disclosure of Potential Conflicts of Interest

Most authors are employees of Transgene, the company that patented mAB H27K15.

Acknowledgments

We thank Guillaume Fichet and Christine Kreuz for their contribution in the macrophage differentiation experiments, Pascal Mercier from Roche for the gift of rituximab, and Pascale Jeannin, Jean-Pierre Abastado, Bruce Acres and Jean-Luc Teillaud for critical reading of the manuscript.

Supplemental Materials

Supplemental materials can be found here: www.landesbioscience.com/journals/mabs/article/25743.

References

1. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012; 119:1810-20; PMID:22186992; http://dx.doi.org/10.1182/blood-2011-09-379214
2. Takayangi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7:292-304; PMID:17380158; http://dx.doi.org/10.1038/nri2062
3. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Chambers SK. Role of CSF-1 in progression of epithelial cancers. J Natl Cancer Inst 2004; 96:1279-87; PMID:15507909; http://dx.doi.org/10.1093/jnci/djh137
4. Hamilton JA, Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 2013; 34:81-9; PMID:23000011; http://dx.doi.org/10.1016/j.ti.2012.08.006
5. Sherr CJ. Colony-stimulating factor-1 receptor. Blood 1990; 75:1-12; PMID:2153629
6. Ide H, Seligson DB, Memarzadeh S, Xin L, Horvath S, Dubey P, et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A 2002; 99:14469-9; PMID:12381783; http://dx.doi.org/10.1073/pnas.222537099
7. Smith HO, Anderson PS, Kuo DY, Goldberg GL, DeVictria CL, Boocock CA, et al. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1995; 1:313-25; PMID:8195878
8. Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol 2009; 5:1429-40; PMID:19903670; http://dx.doi.org/10.2217/fon.09.103
9. Hamme L, Tekmal RR, Naid I, Edelweis MI, Kirma N, Valente PT, et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Cancer Cell 2008; 13:445-51; PMID:18565574; http://dx.doi.org/10.1016/j.jcancer.2008.04.038
10. Scholl SM, Lidereau R, de la Rochefordière A, Le-Nir CC, Mosseri V, Nogués C, et al. Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat 1996; 39:273-83; PMID:8877007; http://dx.doi.org/10.1007/BF01886155
11. Becker S, Warren MK, Haskell S. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. Blood 2000; 96:1279-87; PMID:109082763
33. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasil K, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999; 190:1741-54; PMID:10601350; http://dx.doi.org/10.1084/jem.190.12.1741

34. Hodge JM, Collier FM, Pavlos NJ, Kirkland MA, Nicholson GC. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One 2011; 6:e21462; PMID:21738673; http://dx.doi.org/10.1371/journal.pone.0021462

35. Yazigi K, Rittling SR. Both cell-surface and secreted Csf-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res 2009; 315:2342-52; PMID:19427849; http://dx.doi.org/10.1016/j.yexcr.2009.05.002

36. Sherr CJ, Ashmun RA, Dowling JR, Ohtsuka M, Quan SG, Golde DW, et al. Inhibition of colony-stimulating factor-1 activity by monoclonal antibodies to the human Csf-1 receptor. Blood 1989; 73:1786-93; PMID:2540857

37. Chihara T, Sura S, Hassan R, Churutsitsouchi N, Hiyoshi M, Motoyoshi K, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ 2010; 17:1917-27; PMID:20409731; http://dx.doi.org/10.1038/cdd.2010.60

38. Wang C, Koistinen P, Yang GS, Lyman DW, Shaw E, et al. Inhibition of colony-stimulating factor-1 activity by monoclonal antibodies to the human CSF-1 receptor. Proc Natl Acad Sci U S A 2001; 98:6179-84; PMID:11583400; http://dx.doi.org/10.1073/pnas.101110998

39. Rissanen JP, Ylipahkala H, Fagerlund KM, Long C, Vainanen HK, Halleen JM. Improved methods for testing antiresorptive compounds in human osteoclasts. J Bone Miner Metab 2009; 27:105-9; PMID:19018457; http://dx.doi.org/10.1007/s00774-008-0002-1

40. Akagawa KS. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int J Hematol 2002; 76:27-34; PMID:12138892; http://dx.doi.org/10.1010/BJ02982715

41. Paniagua RT, Chang A, Mariano MM, Steen EA, Wang Q, Lindstrom TM, et al. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res Ther 2010; 12:R32; PMID:20181277; http://dx.doi.org/10.1186/ar2940

42. Risssanen JP, Ylipahkala H, Fagerlund KM, Long C, Vainanen HK, Halleen JM. Improved methods for testing antiresorptive compounds in human osteoclasts. J Bone Miner Metab 2009; 27:105-9; PMID:19018457; http://dx.doi.org/10.1007/s00774-008-0002-1

43. Wang C, Koistinen P, Yang GS, Williams DE, Lyman DW, Shaw E, et al. Inhibition of colony-stimulating factor-1 activity by monoclonal antibodies to the human CSF-1 receptor. Proc Natl Acad Sci U S A 2001; 98:6179-84; PMID:11583400; http://dx.doi.org/10.1073/pnas.101110998